| 產品名稱 | MLN 2238 - Ixazomib |
| 產品貨號 | Axon 2556 CAS [1072833-77-2] MF C14H19BCl2N2O4MW 361.03 Purity: 98% Solubble in DMSO Description Selective and reversible inhibitor of the β5 subunit sites of the 20S proteasome with antitumor activity in various malignancies. MLN 2238 exhibits improved pharmacodynamics and antitumor activity compared with bortezomib in various B-cell lymphoma models, due to a greater tumor to blood ratio of proteasome inhibition that ultimately translates into improved tumor pharmacodynamic response and antitumor activity in several tumor xenograft models.? MLN 2238 is also available as the more stable citrate prodrug MLN 9708 (Axon 2557). KEYWORDS:?MLN 2238 | supplier | Proteasome inhibitor | Ixazomib | MLN2238 | CAS [1072833-77-2] | Ubiquitin | Proteasome 20S | Inhibitor | β5 subunit | B-cell lymphoma | FDA approved | MLN 9708 |
| 產品價格 | 現貨詢價，電話：010-67529703 |
| 產品規格 | |
| 產品品牌 | axonmedchem |
| 產品概述 | |
| 產品詳情 |
MLN 2238 - IxazomibAxon 2556 CAS [1072833-77-2] MF C14H19BCl2N2O4
DescriptionSelective and reversible inhibitor of the β5 subunit sites of the 20S proteasome with antitumor activity in various malignancies. MLN 2238 exhibits improved pharmacodynamics and antitumor activity compared with bortezomib in various B-cell lymphoma models, due to a greater tumor to blood ratio of proteasome inhibition that ultimately translates into improved tumor pharmacodynamic response and antitumor activity in several tumor xenograft models.? MLN 2238 is also available as the more stable citrate prodrug MLN 9708 (Axon 2557). KEYWORDS:?MLN 2238 | supplier | Proteasome inhibitor | Ixazomib | MLN2238 | CAS [1072833-77-2] | Ubiquitin | Proteasome 20S | Inhibitor | β5 subunit | B-cell lymphoma | FDA approved | MLN 9708
Selective and reversible 20S proteasome inhibitor
Chemical name(R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic acid Parent CAS No.[1072833-77-2] |
| 產品資料 |
